A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

NCT03106428 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Multiple Myeloma
Diffuse Large B-cell Lymphoma

Interventions

DRUG: MEDI7247

Sponsor

MedImmune LLC